Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market

Description: The market for psychotherapeutics drugs is about to change dramatically -- and serious pharmaceutical market watchers will want to be prepared. Kalorama's Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs: World Market is the most exhaustive guide available to this booming market and the direction it is headed in the next four years.

Psychotherapeutics treat conditions classified as abnormal behavior, thoughts and feelings that persist for a determined amount of time causing distress or emotional/physical impairment. Depression, anxiety, psychosis, ADHD and nicotine and drug dependence are among the conditions psychotherapeutics treat. Well-known brands such as Prozac™, Zoloft™ and Ritalin ™ have made this a $37 billion market. And according to Kalorama's research, revenues from this area will grow more than 50% by 2010.

Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Market covers this market completely including an overview; surveys of the key corporate players, geographic market breakdowns, and revenue forecasts to 2010 in these key market segments:

Antidepressants
Antipsychotics/Antimanics
Antianxiety Drugs
Stimulants and Non-stimulants for ADHD
Smoking Cessation Drugs, Drug Addiction Treatments, Eating Disorder Treatments and Other Psychotherapeutics

In every category of psychotherapeutics, new competitors are emerging. Kalorama's report provides profiles of thirty-six new psychotherapeutic drugs in the pipeline, their expected approval status, and how they may shake up the marketplace - as well as a complete discussion of the issues and trends that will effect psychotherapeutics.

The report also includes current issues and trends affecting the industry including the increasing number of additional indications pharma companies are seeking for their brands and success stories in this area.

Over 110 tables and figures clearly demonstrate the current and future psychotherapeutic markets.

As part of our complete coverage, the following companies are profiled:

Astellas Pharma, Inc.
AstraZeneca Plc
Biovail Corporation
Bristol-Myers Squibb
Eli Lilly & Company
Forest Laboratories, Inc.
GlaxoSmithKline Plc
H. Lundbeck A/S
Kalorama's trusted information-gathering process provides the most accurate study of the market for anti-depressants, anti-anxiety drugs, ADHD treatments and other psychotherapeutic drugs available today. Information and analysis presented in this report is based on extensive interviews with senior management of top companies and in the psychotherapeutics market. While financial reports, major research literature and government information is culled, information is corroborated and key market insights originate from interviews with industry leaders.

Product managers, marketing managers, business development executives, advertising agency or investment firm executives, as well as information and research center librarians are among the individuals who will find this survey of the changing psychotherapeutics market essential.

Kalorama's Antidepressants, Antipsychotics, Antianxiety Drugs, and other Psychotherapeutics: World Market provides coverage of the following brands:

Nardil
Parnate
Prozac
Paxil
Zoloft
Celexa
Lexapro
Effexor and Effexor XR
Cymbalta
Wellbutrin and Wellbutrin XL and Wellbutrin SR
Serzone
Desyrel
Remeron
Symbyax
Tolvon
Xanax
Ativan
Klonopin
Valium
Versed
BuSpar
Lexotan
Paxil/Seroxat and Paxil CR
Zoloft
Ritalin
Focalin and Focalin XR
Daytrana
Strattera
Concerta
Metadate CD
Adderall and Adderall XR
Chantix/Champix
Zyban
Accomplia
Nicotrol
Subutex
Campral
Methodone
ReVia/Naltrex
Antabuse
Narcan
Vivitrol
Depade
YAZ
SSRIs
Compazine, Serentil, Stelazine, Thorazine
Geodon
Zyprexa
Risperdal, Risperdal Consta
Clozaril
Seroquel
Abilify
Lithobid, Eskalith
Symbyax
Lamictal
EMSAM

Contents:
Chapter One: Executive Summary
Introduction
Scope and Methodology
Size and Growth of the Market
Issues and Trends Affecting Market
Competitive Summary
Company Profiles

Chapter Two: Introduction
Conditions
Depressive Disorders
Depression
Seasonal Affective Disorder
Psychotic Disorders
Bipolar Disorder
Schizophrenia
Anxiety Disorders
Attention Deficit Disorders
Eating Disorders
Addiction Disorders

Condition Statistics
Depression
Dysthymic Disorder
Seasonal Affective Disorder (SAD)
Bipolar Disorder
Psychomotor Agitation
Tourette Syndrome
Schizophrenia
Generalized Anxiety Disorder
Social Anxiety Disorder
Obsessive Compulsive Disorder
Panic Disorder
Post Traumatic Stress Disorder
Phobias
Attention Deficit Disorder (ADD) and Attention Deficit Hyperactivity Disorder (ADHD)
Nicotine, Alcohol, and Drug Addiction
Bulimia/Anorexia
Premenstrual Dysphoric Disorder

History and Growth of the Psychotherapeutic Drug Market
Industry Structure and Product Segments

Chapter Three: Antidepressants
Overview
Description of Depression
Epidemiology of Depression
Economic Impact of Depression
Description of Products
Monoamine Oxidase Inhibitors
Nardil
Parnate

Selective Serotonin Reuptake Inhibitors
Prozac/Sarafem
Paxil/Seroxat and Paxil CR
Zoloft
Celexa
Lexapro

Serotonin and Norepinephrine Reuptake Inhibitors
Effexor and Effexor XR
Cymbalta

Aminoketones
Wellbutrin and Wellbutrin XL and Wellbutrin SR

Phenylpiperazines
Serzone
Desyrel

Tetracyclcs and Miscellaneous
Remeron
Symbyax
Tolvon
EMSAM

Products in Research and Development
Desvenlafaxine succinate
Gepirone ER
Vilazodone
Seroquel SR
Saredutant (SR 48968)
SR 58611
DOV 216,303
Corlux
Valdoxan

Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market

Market Data by Indication

Competitive Analysis

chapter Four: Antipsychotics and Antimanics

Overview
Description of Conditions
Schizophrenia
Bipolar Disorder
Tourette's Syndrome

Epidemiology
Economic Impact
Description of Products
Phenothiazines
Compazine, Serentil, Stelazine, Thorazine
Geodon

Thienobenzodiazepines
Zyprexa

Benzisoxazole Derivatives
Risperdal, Risperdal Consta

Dibenzodiazepine and Dibenzothiazepine Derivatives
Clozaril
Seroquel

Dopamine Partial Agonist
Abilify

Lithium
Lithobid, Eskalith

Miscellaneous
Symbyax
Lamictal

Research and Development
Paliperidone, Paliperidone ER, Paliperidone Palmitate IM
Asenapine
Bifeprunox
Lamictal
Iloperidone (Zomaril)
LIC 477D
Seroquel SR

Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market

Market Data by Indication

Competitive Analysis

chapter Five: Antianxiety Drugs

Overview
Description of Conditions
Economic Impact

Description of Products
Benzodiazepines
Xanax
Ativan
Klonopin
Valium
Versed

Miscellaneous Antianxiety Agents
BuSpar
Lexotan
Prozac/Sarafem
Paxil/Seroxat and Paxil CR
Zoloft
Effexor and Effexor XR

Research and Development
Cipralex
Cymbalta
Lyrica
Desvenlafaxine succinate
DOV 216,303
PDX 00023
Gepirone ER
Saredutant (SR 48968)
SR 58611
Valdoxan

Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market

Market Data by Indication

Competitive Analysis

CHAPTER SIX: CNS Stimulants and Nonstimulant Attention Deficit Hyperactive Disorder Treatments

Overview
Description of Conditions
Economic Impact

Description of Products
Amphetamines
Ritalin
Focalin and Focalin XR
Daytrana

Selective Norepinephrine Reuptake Inhibitors
Strattera

Central Nervous System Stimulants
Concerta
Metadate CD

Sympathomimetic Amines
Adderall and Adderall XR

Research and Development
NRP104/LDX
Guanfacine ER (SPD-503)
SPD-465

Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan Market
ROW Market
chapter Seven: Other Psychotherapeutic Drugs

Overview
Description of Conditions
Eating Disorders - Anorexia and Bulimia
Substance Abuse - Alcohol, Narcotic, Nicotine
Premenstrual Dysphoric Disorder

Economic Impact
Description of Products
Smoking Cessation
Chantix/Champix
Zyban
Accomplia
Nicotrol

Alcohol and Opiate Dependence and Related
Subutex
Campral
Methodone
ReVia/Naltrex
Antabuse
Narcan
Vivitrol
Depade

Bulimia/Anorexia
Prozac

Premenstrual Dysphoric Syndrome
YAZ
SSRIs

Research and Development
Acomplia
Lofexidine
Naltrexone Depot
Lybrel
SSR591813
Cyt002-NicQb
NicVAX

Market Size and Growth
Total World Market
Markets by Geographical Segments
U.S. Market
European Union Market
Japan and ROW Market

Market Data by Indication

Competitive Analysis

Chapter Eight: Issues and Trends Affecting the Psychotherapeutic Drug Market

introduction
Patent Expiration Tactics
Smoking Cessation and Genetic Testing
New Drug Targets
Chapter Nine: The Evolving Psychotherapeutic Drug Market: Market Forecasts
Overview
Total market Size and Forecast
Competitor Analysis

Chapter Ten: Company Profiles
Introduction
Competitive Summary
Astellas Pharma, Inc.
AstraZeneca Plc
Biovail Corporation
Bristol-Myers Squibb
Eli Lilly & Company
Forest Laboratories, Inc.
GlaxoSmithKline Plc
H. Lundbeck A/S
Johnson & Johnson
Otsuka Pharmaceutical Co. Ltd.
Pfizer, Inc.
Shire Pharmaceuticals Group Plc
Wyeth

Appendix
Company Directory
List of Exhibits

Chapter One: Executive Summary
Table 1-1: Market Summary: Total World Psychotherapeutic Drug Market 2003-2010
Figure 1-1: Trending in the World Market for Psychotherapeutic Drugs 2003-2010

Chapter Two: INTRODUCTION
Table 2-1: Estimated World and U.S. Prevalence of Psychotic Conditions or Disorders
Figure 2-1: Estimated World Prevalence of Psychotic Conditions or Disorders
Figure 2-2: Estimated U.S. Prevalence of Psychotic Conditions or Disorders

Chapter Three: ANTIDEPRESSANTS
Table 3-1: Estimated World and U.S. Prevalence of Depression
Figure 3-1: Estimated World and U.S. Prevalence of Depression
Table 3-2: Recent FDA Antidepressant Approvals, 2003-2006 (Product, Generic Name, Manufacturer/Marketer, Approval Date, Patent Expiration Date)
Table 3-3: Antidepressants in Research and Development (Product, Developer, Indication, Phase)
Table 3-4: The World Market for Antidepressant Drugs 2003-2010
Figure 3-2: Trending in the World Market for Antidepressant Drugs, 2003-2010
Table 3-5: The World Market for Antidepressant Drugs by Product Classification (SSRIs, S/NRIs, Others) 2003-2010
Figure 3-3: Trending in the World Market for Antidepressant Drugs by Product Class, 2003-2010
Chapter FOUR: ANTIPSYCHOTICS AND ANTIMANICS

Table 4-1: Estimated World and U.S. Prevalence of Psychotic and Manic Disorders
Table 4-2: Recent FDA Antipsychotic/Antimanic Approvals, 2003-2006 (Product, Generic Name, Manufacturer/Marketer, Approval Date, Patent Expiration Date)
Table 4-3: Antipsychotics and Antimanics in Research and Development (Product, Developer, Indication, Phase)
Table 4-4: World Market : Antipsychotic and Antimanic Drugs, 2003-2010
Table 4-5:: World Market: Antipsychotic and Antimanic Drugs by Product Classification, 2003-2010
Table 4-6: World Market Antipsychotic and Antimanic Drug Market by Geographical Segment, 2003-2010
Table 4-7: Estimated Antipsychotic and Antimanic Drug Sales by Indication, 2005
Table 4-8: World Market : Antipsychotic and Antimanic Drug: Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
Table 4-9: Antipsychotic and Antimanic Drug Market, 2003-2010; Top Antipsychotic and Antimanic Drugs by Estimated Sales and Percent of Market, 2005

Chapter FIVE: ANTIANXIETY DRUGS

Table 5-1: Estimated World and U.S. Prevalence of Conditions
Table 5-2: Research and Development: Antianxiety Drugs
Table 5-3: World Market Antianxiety Drugs, 2003-2010
Chapter Six: CNS Stimulants and Nonstimulant Attention Deficit Hyperactive Disorder Treatments

Table 6-1: Estimated World and U.S. Prevalence of Conditions

Figure 6-1: Estimated World and U.S. Prevalence of Conditions

Table 6-2: Recent Stimulant Approvals, 2003-2006

Table 6-3: Research and Development: Stimulants

Table 6-4: World Market Stimulants and Non-Stimulants in the ADHD Market, 2003-2010

Figure 6-2: World Market: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010

Table 6-5: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment, 2003-2010

Figure 6-3: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment, 2003-2010

Figure 6-4: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment Percent Distribution, 2003-2010

Figure 6-5: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment and Percent Market Share, 2005

Figure 6-6: World Market: Stimulants and Non-Stimulants in the ADHD Market by Geographical Segment and Percent Market Share, 2010

Table 6-6: World Market: Stimulants and Non-Stimulants in ADHD Treatment Leading Suppliers Shares by Market Revenues, 2005 and Projected 2010

Figure 6-7: World Market: Stimulants and Non-Stimulants in ADHD Treatment, 2003-2010

Figure 6-8: World Market: Stimulants and Non-Stimulants in ADHD Treatment, 2005

Table 6-7: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010

Figure 6-9: Stimulants and Non-Stimulants in the ADHD Market, 2003-2010

Chapter Seven: Other Psychotherapeutic Drugs

Table 7-1: Estimated World Prevalence of Conditions
Figure 7-1: Estimated World Prevalence of Conditions
Table 7-2: Recent Other Psychotherapeutic Drug Approvals
Table 7-3: Research and Development: Other Psychotherapeutic Drugs
Figure 7-2: Research and Development: Other Psychotherapeutic Drugs
Table 7-4: World Market: Other Psychotherapeutic Drugs, 2003-2010
Figure 7-2: World Market: Other Psychotherapeutic Drugs, 2003-2010
Table 7-5: World Market: Other Psychotherapeutic Drugs by Product Classification, 2003-2010
Figure 7-3: Other Psychotherapeutic Drugs by Product Classification Revenues,
Figure 7-4: Other Psychotherapeutic Drugs by Product Classification and Percent Distribution,
Figure 7-5: Other Psychotherapeutic Drugs by Product Classification and Percent Market Share, 2005
Figure 7-6: Other Psychotherapeutic Drugs by Product Classification and Percent Market Share, 2010
Table 7-6: Other Psychotherapeutic Drug Market by Geographical Segment
Figure 7-7: World Market: Other Psychotherapeutic Drug Market by Geographical Segment, 2003-2010
Figure 7-8: World Market: Other Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share, 2005
Figure 7-9: World Market: Other Psychotherapeutic Drug Market by Geographical Segment and Percent Market Share, 2010
Table 7-7: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005 (in million of dollars at the manufacturers level)
Figure 7-10: Estimated Other Psychotherapeutic Drug Sales by Indication, 2005
Table 7-8: World Market Other Psychotherapeutic Drugs Leading Suppliers Shares by Market Revenues, Estimated 2005 and Projected 2010
Figure 7-11: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Estimated 2005
Figure 7-12: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Projected 2010
Figure 7-13: World Market Other Psychotherapeutic Drugs Leading Suppliers Market Share, Projected 2010
Table 7-9: Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of Market, 2005 (in million of dollars at the manufacturers level)
Figure 7-14: Other Psychotherapeutic Drug Market, 2003-2010 Top Drugs by Estimated Sales and Percent of Market, 2005

CHAPTER EIGHT: ISSUES AND TRENDS AFFECTING THE PSYCHOTHERAPEUTIC DRUG MARKET
Table 8-1: Patent Data

CHAPTER NINE: THE EVOLVING PSYCHOTHERAPEUTIC DRUG MARKET
Table 9-1: Psychotherapeutic Drug Market, 2003-2010
Figure 9-1: Psychotherapeutic Drug Market, 2003-2010
Figure 9-2: Psychotherapeutic Drug Market by Percent and Treatment Segment, 2005
Figure 9-3: Psychotherapeutic Drug Market by Percent and Treatment Segment, 2010
Table 9-2: Leading Suppliers, Products, and Segments of Participation 2005
Figure 9-4: Leading Suppliers Market Shares 2005

Ordering:
Order Online - http://www.researchandmarkets.com/reports/2860735/
Order by Fax - using the form below
Order by Post - print the order form below and send to
Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit
http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Psychotherapeutics: Antidepressants, Antipsychotics, Antianxiety Drugs, World Market
Web Address: http://www.researchandmarkets.com/reports/2860735/
Office Code: SCD2SI18

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Quantity</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td>☐ USD 995</td>
</tr>
<tr>
<td>Hard Copy</td>
<td>☐ USD 3900 + USD 57 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprise</td>
<td>☐ USD 7000</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: ____________________________ Mr ☐ Mrs ☐ Dr ☐ Miss ☐ Ms ☐ Prof ☐
First Name: ________________________ Last Name: ________________________
Email Address: * ______________________
Job Title: __________________________
Organisation: _______________________
Address: ___________________________
City: ______________________________
Postal / Zip Code: __________________
Country: ___________________________
Phone Number: ______________________
Fax Number: ________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information
Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:
Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:
Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: ____________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp